Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subretinal surabgene lomparvovec versus PRN ranibizumab in neovascular age-related macular degeneration
MOH_2026-02-23_015677Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of surabgene lomparvovec and ranibizumab in exudative macular degeneration (3 arms), sponsored by AbbVie Inc. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
surabgene lomparvovecranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2026-02-23_015677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-23_015677.